Chronic lymphocytic leukemia/small lymphocytic lymphoma, version 1.2015.
Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) are different manifestations of the same disease, which are managed in the same way. The advent of novel monoclonal antibodies (ofatumumab and obinutuzumab) led to the development of effective chemoimmunotherapy regimens. The recently approved small molecule kinase inhibitors (ibrutinib and idelalisib) are effective treatment options for CLL in elderly patients with decreased tolerance for aggressive regimens and in patients with poor prognostic features who do not benefit from conventional chemoimmunotherapy regimens. This portion of the NCCN Guidelines for Non-Hodgkin's Lymphomas describes the recent specific to the incorporation of recently approved targeted therapies for the management of patients with newly diagnosed and relapsed or refractory CLL/SLL.
Andrew D
AD
Zelenetz
Leo I
LI
Gordon
William G
WG
Wierda
Jeremy S
JS
Abramson
Ranjana H
RH
Advani
C Babis
CB
Andreadis
Nancy
N
Bartlett
John C
JC
Byrd
Myron S
MS
Czuczman
Luis E
LE
Fayad
Richard I
RI
Fisher
Martha J
MJ
Glenn
Thomas M
TM
Habermann
Nancy Lee
NL
Harris
Richard T
RT
Hoppe
Steven M
SM
Horwitz
Christopher R
CR
Kelsey
Youn H
YH
Kim
Susan
S
Krivacic
Ann S
AS
LaCasce
Auayporn
A
Nademanee
Pierluigi
P
Porcu
Oliver
O
Press
Rachel
R
Rabinovitch
Nishitha
N
Reddy
Erin
E
Reid
Ayman A
AA
Saad
Lubomir
L
Sokol
Lode J
LJ
Swinnen
Christina
C
Tsien
Julie M
JM
Vose
Lynn
L
Wilson
Joachim
J
Yahalom
Nadeem
N
Zafar
Mary
M
Dwyer
Hema
H
Sundar
D000465:Algorithms; D015897:Comorbidity; D019468:Disease Management; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000175:diagnosis* / Q000453:epidemiology / Q000209:etiology / Q000628:therapy*; D009367:Neoplasm Staging; D011379:Prognosis